Related Experiment Video

Updated: Feb 20, 2026

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

1.5K

MAGE-A11 expression contributes to cisplatin resistance in head and neck cancer

Stefan Hartmann1,2, Leonie Zwick3, Mario J J Scheurer3

  • 1Department of Oral and Maxillofacial Plastic Surgery, University Hospital Würzburg, Pleicherwall 2, 97070, Würzburg, Germany. hartmann_s2@ukw.de.

Clinical Oral Investigations
|October 17, 2017
PubMed
Abstract

Insights

Melanoma-associated antigen A11 (MAGE-A11) expression correlates with cisplatin resistance in head and neck cancer. Overexpression of MAGE-A11 reduces treatment efficacy and apoptosis, indicating its role in treatment failure.

Area of Science:

  • Oncology
  • Cancer Biology
  • Molecular Medicine

Background:

  • Head and neck cancer (HNC) treatment often involves cisplatin chemotherapy.
  • Melanoma-associated antigens (MAGEs) are implicated in various cancers.
  • The role of MAGEs in HNC cisplatin resistance remains unclear.

Purpose of the Study:

  • To investigate the role of MAGEs in cisplatin treatment response in HNC.
  • To determine the correlation between MAGE-A expression and cisplatin efficacy.
  • To assess the functional impact of MAGE-A11 overexpression on HNC cells.

Main Methods:

  • Cisplatin efficacy was assessed using crystal violet assays in four HNC cell lines.
  • MAGE-A expression levels were quantified via RT-qPCR.
  • Spearman's correlation analysis identified associations between MAGE-A expression and cisplatin efficacy.
  • MAGE-A11 overexpression cell line was created to evaluate proliferation, apoptosis (Annexin V flow cytometry), and cisplatin response.

Main Results:

  • MAGE-A11 expression showed a significant correlation (r=1.000, p=0.0417) with reduced cisplatin efficacy.
  • MAGE-A11 overexpression did not affect proliferation but decreased cisplatin cytotoxicity and apoptosis rates.
  • MAGE-A11 overexpression induced mouse double minute 2 homolog (MDM2) expression.

Conclusions:

  • MAGE-A11 expression contributes to cisplatin resistance in head and neck cancer.
  • MAGE-A11 serves as a negative predictive marker for cisplatin treatment outcomes in HNC.
  • Targeting MAGE-A11 may offer novel therapeutic strategies for overcoming cisplatin resistance.
Keywords:
CisplatinHead and neck cancerMage-A11Melanoma-associated antigens

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.2K
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.4K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
6.7K
Mismatch Repair01:36

Mismatch Repair

Overview
43.9K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K